Glycogen storage disease type IV
For the main page on glycogen storage disease, please click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vellayat Ali M.B.B.S[2]
Synonyms and keywords: Andersen Disease; Brancher deficiency; Amylopectinosis; Glycogen Branching Enzyme Deficiency; Glycogenosis IV; Adult polyglucosan body disease (APBD)
Overview
Historical Perspective
- In 1952, B Illingworth and GT Cori observed accumulation of an abnormal glycogen (resembling amylopectin) in the liver of a patient with von Gierke's disease. They postulated this finding to a different type of enzymatic deficiency, and thus to a different type of glycogen storage disease.[1]
- In 1956, DH Andersen, an American pathologist and pediatrician, reported the first clinical case of the disease as "familial cirrhosis of the liver with storage of abnormal glycogen".[2]
- In 1966, BI Brown and DH Brown clearly demonstrated the deficiency of glycogen branching enzyme (alpha-1,4-glucan: alpha-1,4-glucan 6-glycosyl transferase) in a case of Type IV glycogenosis.[3]
Classification
There is no established system for the classification of GSD Type IV. The deficiency of GBE affecting liver, brain, heart, and skeletal muscles leads to variable clinical presentations. Based on organ/tissue involvement, age of onset and clinical features, Andersen disease can be segregated into various forms [4] as below:
Form of Presentation | Age of
Onset |
Clinical Features | |
---|---|---|---|
Classic Hepatic Form | 0-18 mo | Infants with classic hepatic form present with failure to thrive, hypotonia and hepatosplenomegaly. The disease progresses to portal hypertension, ascites, and liver failure, leading to death by 5 years of age.[5] | |
Neuro-
Muscular Form |
Perinatal | In utero | Prenatal symptoms include, polyhydramnios, hydrops fetalis, and decreased fetal movement; at birth severe hypotonia is observed requiring mechanical ventilation for respiratory support.[6][7] Cardiac findings like progressive cardiomyopathy may also be present.[8] |
Congenital | At birth | Newborns may present with severe hypotonia, hyporeflexia, cardiomyopathy, depressed respiration and neuronal involvement, leading to death in early infancy.[9] | |
Late childhood | 0-18 yrs | Presents in childhood at any age with myopathy as exercise intolerance, and cardiopathy as exertional dyspnea; and congestive heart failure in progressed cases.[10] | |
Adult | >18-21 yrs (any age in adulthood) | May present as isolated myopathy[11] or as Adult Polyglucosan Body Disease (APBD)[12] |
Adult Polyglucosan Body Disease (APBD)
- Adult Polyglucosan body disease is one of the neuromuscular variant of GSD Type IV.
- It is a late-onset, slowly progressive disorder of the nervous system GBE deficiency in a subgroup of patients of Ashkenazi Jewish origin.[13]
- Typically, the first clinical manifestation is of urinary incontinence secondary to neurogenic bladder.[14]
- This is followed by gait disturbance (due to spastic paraplegia) and lower limb paresthesias.[15]
- Patients deteriorate slowly over years and lose ability to ambulate independently, and develop paralysis of the upper limbs as well.[16]
- Progressive dementia is also seen in these patients.[17]
- The pathologic hallmark of the disorder is the widespread accumulation of round, intracellular polyglucosan bodies throughout the nervous system, which are confined to neuronal and astrocytic processes.OMIM
- The disease often leads to premature death.[18]
Pathophysiology
Pathogenesis
- Glycogen storage disease type IV is an autosomal recessive genetic disorder which results due to deficiency of glycogen branching enzyme (GBE).[19]
- During Glycogenesis, the branching enzyme introduces branches to growing glycogen chains by transferring α-1,4-linked glucose monomers from the outer end of a chain into an α-1,6 position of the same or neighboring glycogen chain.[20]
- Deficiency of GBE affects the branching process, yielding a polysaccharide which has fewer branching points and longer outer chains, thus resembling amylopectin. This new amylopectin-like structure is also known as polyglucosan.[21]
- The enzyme deficiency affects all the bodily tissues; but liver, heart, skeletal muscles, and the nervous system are mostly affected.
- The abnormally branched glycogen accumulates as intracytoplasmic non membrane-bound inclusions in hepatocytes, myocytes, and neuromuscular system; where it increases osmotic pressure within cells, causing cellular swelling and death.[22]
- The altered structure also renders glycogen to become less soluble, and this is thought to lead into a foreign body reaction causing fibrosis, and finally culminating in liver failure. [23]
- In skeletal muscle, accumulation leads to muscle weakness, fatigue, exercise intolerance, and muscular atrophy.National Organization for Rare Disorders (NORD): rarediseases.org/rare-diseases/andersen-disease-gsd-iv/
- The heart may be affected with a wide spectrum of cardiomyopathy; from dilated to hypertrophic and from asymptomatic to decompensated heart failure may occur.[24]
- Although exact mechanism for this pathology is not known, glycogen deposition in the myocardium is thought to initiate signaling pathways which cause sarcomeric hypertrophy, resulting in hypertrophic cardiomyopathy.[25]
Genetics
- Glycogen branching enzyme is a 702 amino acid protein encoded by GBE1 gene mapped to chromosome 3p12.2. HUGO Gene Nomenclature Committee https://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=HGNC:4180 The Universal Protein Resource (UniProt) http://www.uniprot.org/uniprot/Q04446
- Mutations in the GBE1 are responsible for enzymatic deficiency, and so far 40 pathogenic variants have been identified in individuals with GSD IV or adult-onset polyglucosan body disease (APBD).[26]
Causes
- The cause of GSD type IV is variable deficiency of glycogen branching enzyme (GBE).
- The deficiency is due to various mutations of GBE1 gene encoding the single polypeptide protein.
Differentiating ((Page name)) from Other Diseases
- Comparisons may be useful for a differential diagnosis as a number of other disease conditions with clinical features may present similar to those associated with GSD Type IV.
- Presenting as hepatomegaly in infancy, the following glycogen metabolism disorders should be differentiated from GSD Type IV;
- GSD Type I
- GSD Type III
- GSD Type VI
- Hepatic Phosphorylase b Kinase Deficiency
- Metabolic disorders presenting with muscle weakness/myopathy during infancy should also be considered;
- Muscle glycogen synthase deficiency (GSD0b)
- Lysosomal acid maltase deficiency (GSD II)
- Glycogen debrancher deficiency (GSD III)
- Muscle phosphorylase deficiency (GSD V)
- Aldolase A deficiency (GSD XII)
- Glycogenin-1 deficiency (GSD XV)
Epidemiology and Demographics
Frequency
- The frequency of all glycogen storage diseases is estimated to be 1 in 20,000 to 25,000 live births, while GSD IV is estimated to occur in 1 in 600,000 to 800,000 individuals worldwide. NORD GHR https://ghr.nlm.nih.gov/condition/glycogen-storage-disease-type-iv#statistics
SEX
- Males and females appear to be affected in relatively equal numbers [NORD] because the deficiency of glycogen-branching enzyme activity is inherited as an autosomal-recessive trait.
RACE
- Familial aggregation is observed in about 30% of adult polyglucosan body disease cases, especially among Ashkenazi Jewish populations. NORD
Risk Factors
- As GSD type IV is an inherited disease with autosomal recessive pattern, a positive family history is a potent risk factor.
- Each sibling of a diseased individual has a 25% probability of being affected, a 50% probability of being a carrier, and a 25% probability of being unaffected and not a carrier. GeneReview
Screening
- Currently, there is no screening guideline recommendation.
- In some cases, the disease may be diagnosed prenatally via chorionic villus sampling (CVS) and amniocentesis.
Prenatal Diagnosis
- After genetic confirmation of the affected cases, future pregnancies can be monitored by determining branching enzyme activity and DNA analysis of chorionic villi or cultured amniocytes.[27] [28]
- Histological analysis of placental tissue may also be used in prenatal diagnosis of the disease.[29]
Natural History, Complications, and Prognosis
- GSD IV is a very rare disorder.
- Liver transplantation has been found to prevent progression of the disease.
- Classic hepatic form begins in first year of life, progresses to hepatic failure, and death occurs by 5 years of age.
- Most children with this condition die before two years of age, in rare cases progression to liver dysfunction does not occur.
Diagnosis
- Glycogen storage disease type IV should be suspected in a patient based on clinical features and finding abnormally branched glycogen accumulation in muscle or liver tissue.
Diagnostic Study of Choice
- The diagnosis is confirmed by demonstration of glycogen branching enzyme (GBE) deficiency in liver, muscle, or skin fibroblasts [PMID: 6220706], and/or
- Molecular genetic testing of GBE1 gene for mutations https://www.ncbi.nlm.nih.gov/books/NBK115333/
History and Symptoms
· Classically, the patient presents in their first year of life with complaints of failure to thrive and hepatosplenomegaly.[17]
· As the disease progress towards cirrhosis, features of hepatic failure become evident.
· Rarely in some children, hepatomegaly is the only presentation and disease does not progress to liver failure. PubMed: 8830177 [PubMed: 3162725]
· In perinatal variant, affected newborns may have a prenatal history of polyhydramnios, reduced utero fetal movements and fetal hydrops. At birth, lack of active movements, sucking, and swallowing is noted. PMID 15669676
· Individuals with late childhood form usually present in the second decade of life with complaints of exercise intolerance and exertional dyspnea secondary to muscle involvement and cardiomyopathy respectively.[20] [21]
Physical Examination
Findings on physical examination of patients with glycogen storage disease type IV vary with respect to the disease variant and organ system involved.
In infants with the classic (hepatic) form of GSD type IV, findings depicting liver involvement predominate:
· Abdominal protuberance
· Hepatosplenomegaly [17]
· Signs and symptoms of portal hypertension [17]
Newborns with perinatal form of disease may show:
· Poor respiratory effort at birth [7]
· Hyporeflexia [PubMed: 15452297]
· Severely decreased muscle tone [PubMed: 4502299] [PubMed: 8059607]
Patients with ‘late childhood form’ of disease may have:
· dysmorphic features [PubMed: 7683169]
· myopathic faces, hypotonia, and waddling gait with hyperlordosis [PubMed: 15452297]
Laboratory Findings
- Liver functions tests:
- ALT and AST are typically elevated in the hepatic subtype of disease.https://www.ncbi.nlm.nih.gov/books/NBK115333/#gsd4.Diagnosis
- Decreased albumin levels, prolonged partial thromboplastin time (PTT) and prothrombin time (PT) point to progressive liver dysfunction. https://www.ncbi.nlm.nih.gov/books/NBK115333/#gsd4.Diagnosis
- GBE activity
- Decreased activity of glycogen branching enzyme is found in the liver, leukocytes, erythrocytes and fibroblasts [PMID:11949934] PMID:2972882
- Creatinine Kinase levels:
- CK levels are usually elevated, demonstrating muscle pathology, in the neuromuscular forms of the disease.
- Liver biopsy
- Liver biopsy shows accumulation of abnormal glycogen in hepatocytes. The deposits stain strongly positive with periodic acid-Schiff (PAS), appear brown with iodine, and are only partially digested by diastase. PMID:1067751
- The deposits appear precipitated and are centrally placed in the hepatocytes, while nuclei are eccentric in position. PMID:1067751
- . PMID:1067751
- Chitotriosidase levels:
- Plasma chitotriosidase levels are noted to be elevated in GSD Type IV. PMID: 15669690
X-ray
- Chest radiography is usually not vital in establishing diagnosis.
- In patients with heart involvement, pleural effusions and cardiomegaly may be observed. PMID:3474393
Electrocardiogram
- Although there are no specific EKG findings associated with the disease, after the initial diagnosis, a baseline electrocardiogram is suggested to access for cardiomyopathy. GeneReview
Echocardiography
- In patients with symptoms of heart failure, echocardiography may show evidence of cardiomyopathy. PMID:20833045
Ultrasonography
- Abdominal ultrasound examination is done in the initial workup of the disease.
- It may show hepatosplenomegaly and coarse echo pattern of the liver.
CT scan
- CT scan is usually not required.
- If done to investigate complications of the disease, cirrhotic changes in liver parenchyma may be observed.
MRI
- Magnetic resonance imaging is routinely not required for the diagnostic purposes.
- When done in patients with CNS involvement and adult polyglucosan body disease (APBD), MRI of the head may reveal leukoencephalopathy and cortical atrophy. MRI typically demonstrates:
- medullary and spinal atrophy,
- mild thinning of corpus callosum
- symmetric periventricular white matter changes with occipital predominance. (ISSN: 1531-8249)MedSke
Treatment
Medical Therapy
- There is no specific treatment available for the disease.
- The mainstay of treatment is to provide symptomatic and supportive care through coordinated efforts of a multidisciplinary team consisting of healthcare professionals.
- For patients with progressive liver dysfunction, liver transplantation is the only treatment option PMID :10603098, while symptomatic care involves treating complications i.e. ascites, portal hypertension, variceal bleeds, and coagulopathy.
Liver transplant surgery
In patients with classic glycogen-storage disease type IV, liver transplantation is the most effective treatment. [[null 10], [null 11], [null 12]] Practice guidelines for the evaluation of the patient for liver transplantation have been established by the American Association for the Study of Liver Diseases. null 13
Immediate complications of liver transplantation include postoperative complications and organ rejection. Because glycogen-storage disease type IV is a multisystem disorder, the long-term success of liver transplantation and its effect on the disease progression in other organs is unclear.
Although several patients have reportedly experienced decreased progression and systemic regression after hepatic allografting, presumably due to systemic microchimerism, some patients develop progressive accumulation of abnormal glycogen in other organs after transplantation, ultimately leading to death.
References
- ↑ ILLINGWORTH B, CORI GT (1952). "Structure of glycogens and amylopectins. III. Normal and abnormal human glycogen". J Biol Chem. 199 (2): 653–60. PMID 13022672.
- ↑ ANDERSEN DH (1956). "Familial cirrhosis of the liver with storage of abnormal glycogen". Lab. Invest. 5 (1): 11–20. PMID 13279125.
- ↑ Hawlina A, Osswald H (May 1979). "Cyclic nucleotides in renal tissue and urine during graded expansion of extracellular fluid volume in intact and acutely parathyroidectomized rats". Res Exp Med (Berl). 175 (2): 139–48. PMID 224432.
- ↑ L'herminé-Coulomb A, Beuzen F, Bouvier R, Rolland MO, Froissart R, Menez F, Audibert F, Labrune P (December 2005). "Fetal type IV glycogen storage disease: clinical, enzymatic, and genetic data of a pure muscular form with variable and early antenatal manifestations in the same family". Am. J. Med. Genet. A. 139A (2): 118–22. doi:10.1002/ajmg.a.30945. PMID 16278887.
- ↑ Bao Y, Kishnani P, Wu JY, Chen YT (February 1996). "Hepatic and neuromuscular forms of glycogen storage disease type IV caused by mutations in the same glycogen-branching enzyme gene". J. Clin. Invest. 97 (4): 941–8. doi:10.1172/JCI118517. PMC 507139. PMID 8613547.
- ↑ Escobar LF, Wagner S, Tucker M, Wareham J (October 2012). "Neonatal presentation of lethal neuromuscular glycogen storage disease type IV". J Perinatol. 32 (10): 810–3. doi:10.1038/jp.2011.178. PMID 23014386.
- ↑ Janecke AR, Dertinger S, Ketelsen UP, Bereuter L, Simma B, Müller T, Vogel W, Offner FA (November 2004). "Neonatal type IV glycogen storage disease associated with "null" mutations in glycogen branching enzyme 1". J. Pediatr. 145 (5): 705–9. doi:10.1016/j.jpeds.2004.07.024. PMID 15520786.
- ↑ Janecke AR, Dertinger S, Ketelsen UP, Bereuter L, Simma B, Müller T, Vogel W, Offner FA (November 2004). "Neonatal type IV glycogen storage disease associated with "null" mutations in glycogen branching enzyme 1". J. Pediatr. 145 (5): 705–9. doi:10.1016/j.jpeds.2004.07.024. PMID 15520786.
- ↑ Renwick AG, Oliver JF (July 1973). "The aromatization of (7 -3H) androstenedione by human placental mitochondria". Steroids. 22 (1): 123–32. PMID 4146814.
- ↑ Renwick AG, Oliver JF (July 1973). "The aromatization of (7 -3H) androstenedione by human placental mitochondria". Steroids. 22 (1): 123–32. PMID 4146814.
- ↑ Goebel HH, Shin YS, Gullotta F, Yokota T, Alroy J, Voit T, Haller P, Schulz A (January 1992). "Adult polyglucosan body myopathy". J. Neuropathol. Exp. Neurol. 51 (1): 24–35. PMID 1311021.
- ↑ Bruno C, Servidei S, Shanske S, Karpati G, Carpenter S, McKee D, Barohn RJ, Hirano M, Rifai Z, DiMauro S (January 1993). "Glycogen branching enzyme deficiency in adult polyglucosan body disease". Ann. Neurol. 33 (1): 88–93. doi:10.1002/ana.410330114. PMID 8494336.
- ↑ Lossos A, Meiner Z, Barash V, Soffer D, Schlesinger I, Abramsky O, Argov Z, Shpitzen S, Meiner V (December 1998). "Adult polyglucosan body disease in Ashkenazi Jewish patients carrying the Tyr329Ser mutation in the glycogen-branching enzyme gene". Ann. Neurol. 44 (6): 867–72. doi:10.1002/ana.410440604. PMID 9851430.
- ↑ Mochel F, Schiffmann R, Steenweg ME, Akman HO, Wallace M, Sedel F, Laforêt P, Levy R, Powers JM, Demeret S, Maisonobe T, Froissart R, Da Nobrega BB, Fogel BL, Natowicz MR, Lubetzki C, Durr A, Brice A, Rosenmann H, Barash V, Kakhlon O, Gomori JM, van der Knaap MS, Lossos A (September 2012). "Adult polyglucosan body disease: Natural History and Key Magnetic Resonance Imaging Findings". Ann. Neurol. 72 (3): 433–41. doi:10.1002/ana.23598. PMC 4329926. PMID 23034915.
- ↑ Mochel F, Schiffmann R, Steenweg ME, Akman HO, Wallace M, Sedel F, Laforêt P, Levy R, Powers JM, Demeret S, Maisonobe T, Froissart R, Da Nobrega BB, Fogel BL, Natowicz MR, Lubetzki C, Durr A, Brice A, Rosenmann H, Barash V, Kakhlon O, Gomori JM, van der Knaap MS, Lossos A (September 2012). "Adult polyglucosan body disease: Natural History and Key Magnetic Resonance Imaging Findings". Ann. Neurol. 72 (3): 433–41. doi:10.1002/ana.23598. PMC 4329926. PMID 23034915.
- ↑ Mochel, Fanny; Schiffmann, Raphael; Steenweg, Marjan E.; Akman, Hasan O.; Wallace, Mary; Sedel, Frédéric; Laforêt, Pascal; Levy, Richard; Powers, J. Michael; Demeret, Sophie; Maisonobe, Thierry; Froissart, Roseline; Da Nobrega, Bruno Barcelos; Fogel, Brent L.; Natowicz, Marvin R.; Lubetzki, Catherine; Durr, Alexandra; Brice, Alexis; Rosenmann, Hanna; Barash, Varda; Kakhlon, Or; Gomori, J. Moshe; van der Knaap, Marjo S.; Lossos, Alexander (2012). "Adult polyglucosan body disease: Natural History and Key Magnetic Resonance Imaging Findings". Annals of Neurology. 72 (3): 433–441. doi:10.1002/ana.23598. ISSN 0364-5134.
- ↑ Rifai Z, Klitzke M, Tawil R, Kazee AM, Shanske S, DiMauro S, Griggs RC (January 1994). "Dementia of adult polyglucosan body disease. Evidence of cortical and subcortical dysfunction". Arch. Neurol. 51 (1): 90–4. PMID 8274116.
- ↑ Mochel F, Schiffmann R, Steenweg ME, Akman HO, Wallace M, Sedel F, Laforêt P, Levy R, Powers JM, Demeret S, Maisonobe T, Froissart R, Da Nobrega BB, Fogel BL, Natowicz MR, Lubetzki C, Durr A, Brice A, Rosenmann H, Barash V, Kakhlon O, Gomori JM, van der Knaap MS, Lossos A (September 2012). "Adult polyglucosan body disease: Natural History and Key Magnetic Resonance Imaging Findings". Ann. Neurol. 72 (3): 433–41. doi:10.1002/ana.23598. PMC 4329926. PMID 23034915.
- ↑ Lee, Yi-Ching; Chang, Chia-Jung; Bali, Deeksha; Chen, Yuan-Tsong; Yan, Yu-Ting (2011). "Glycogen-branching enzyme deficiency leads to abnormal cardiac development: novel insights into glycogen storage disease IV". Human Molecular Genetics. 20 (3): 455–465. doi:10.1093/hmg/ddq492. ISSN 1460-2083.
- ↑ Froese, D. Sean; Michaeli, Amit; McCorvie, Thomas J.; Krojer, Tobias; Sasi, Meitav; Melaev, Esther; Goldblum, Amiram; Zatsepin, Maria; Lossos, Alexander; Álvarez, Rafael; Escribá, Pablo V.; Minassian, Berge A.; von Delft, Frank; Kakhlon, Or; Yue, Wyatt W. (2015). "Structural basis of glycogen branching enzyme deficiency and pharmacologic rescue by rational peptide design". Human Molecular Genetics. 24 (20): 5667–5676. doi:10.1093/hmg/ddv280. ISSN 0964-6906.
- ↑ Tay SK, Akman HO, Chung WK, Pike MG, Muntoni F, Hays AP, Shanske S, Valberg SJ, Mickelson JR, Tanji K, DiMauro S (April 2004). "Fatal infantile neuromuscular presentation of glycogen storage disease type IV". Neuromuscul. Disord. 14 (4): 253–60. doi:10.1016/j.nmd.2003.12.006. PMID 15019703.
- ↑ Thon VJ, Khalil M, Cannon JF (April 1993). "Isolation of human glycogen branching enzyme cDNAs by screening complementation in yeast". J. Biol. Chem. 268 (10): 7509–13. PMID 8463281.
- ↑ Howell, R. Rodney (1991). "Continuing Lessons from Glycogen Storage Diseases". New England Journal of Medicine. 324 (1): 55–56. doi:10.1056/NEJM199101033240111. ISSN 0028-4793.
- ↑ Aksu, Tolga; Colak, Ayse; Tufekcioglu, Omac (2012). "Cardiac Involvement in Glycogen Storage Disease Type IV: Two Cases and the Two Ends of a Spectrum". Case Reports in Medicine. 2012: 1–4. doi:10.1155/2012/764286. ISSN 1687-9627.
- ↑ Watkins, Hugh; Schwartz, Robert S.; Ashrafian, Houman; Redwood, Charles (2011). "Inherited Cardiomyopathies". New England Journal of Medicine. 364 (17): 1643–1656. doi:10.1056/NEJMra0902923. ISSN 0028-4793.
- ↑ Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean L, Stephens K, Amemiya A, Magoulas PL, El-Hattab AW. PMID 23285490. Vancouver style error: initials (help); Missing or empty
|title=
(help) - ↑ Akman HO, Karadimas C, Gyftodimou Y, Grigoriadou M, Kokotas H, Konstantinidou A, Anninos H, Patsouris E, Thaker HM, Kaplan JB, Besharat I, Hatzikonstantinou K, Fotopoulos S, Dimauro S, Petersen MB (October 2006). "Prenatal diagnosis of glycogen storage disease type IV". Prenat. Diagn. 26 (10): 951–5. doi:10.1002/pd.1533. PMID 16874838.
- ↑ Brown BI, Brown DH (March 1989). "Branching enzyme activity of cultured amniocytes and chorionic villi: prenatal testing for type IV glycogen storage disease". Am. J. Hum. Genet. 44 (3): 378–81. PMC 1715438. PMID 2521770.
- ↑ Konstantinidou AE, Anninos H, Dertinger S, Nonni A, Petersen M, Karadimas C, Havaki S, Marinos E, Akman HO, DiMauro S, Patsouris E (April 2008). "Placental involvement in glycogen storage disease type IV". Placenta. 29 (4): 378–81. doi:10.1016/j.placenta.2008.01.005. PMID 18289670.